Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.85

-4.5%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (10834)	3/4/2004 5:35:30 PM
From: Biomaven	Read Replies (2) of 52153

ELN/BIIB One cautionary note pointed out to me by a friend is that they are running a combined Avonex/Antegren trial. So there is a possibility of actually bolstering Avonex use - it will be the only existing drug already studied with Antegren. In the BIIB CC there seemed to be an acknowledgement that some amount of cannibalization is likely. Without seeing the actual trial results in both the monotherapy and combination therapy it's hard to know how this will play out. When I get a chance I should go back and look at the Phase II Antegren data that was published.Antegren can only be a negative for SRO and Teva though. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next